SuperworthMadrigal Pharmaceuticals EPS MDGL
Diluted earnings per share by quarter and over the last twelve months, from 2010.
- Last 12 months, to Jun 30, 2026
- −$12.87
- Latest quarter, Q2 FY26
- −$1.99
- Fiscal year 2025
- −$11.74
Madrigal Pharmaceuticals' earnings per share was −$12.87 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$1.99.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$11.74 | n/a |
| FY2024 | −$22.11 | n/a |
| FY2023 | −$19.94 | n/a |
| FY2022 | −$17.23 | n/a |
| FY2021 | −$14.61 | n/a |
| FY2020 | −$13.09 | n/a |
| FY2019 | −$5.45 | n/a |
| FY2018 | −$2.21 | n/a |
| FY2017 | −$2.54 | n/a |
| FY2016 | −$28.31 | n/a |
| FY2015 | −$25.16 | n/a |
| FY2014 | −$31.50 | n/a |
| FY2013 | −$44.45 | n/a |
| FY2012 | −$37.10 | n/a |
| FY2011 | −$35.35 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$1.99 | n/a | −$12.87 | |
| Q1 FY26 | −$3.25 | n/a | −$12.38 | |
| Q4 FY25 | −$2.55 | n/a | −$11.74 | |
| Q3 FY25 | −$5.08 | n/a | −$11.90 | |
| Q2 FY25 | −$1.50 | n/a | −$11.74 | |
| Q1 FY25 | −$2.61 | n/a | −$17.34 | |
| Q4 FY24 | −$2.71 | n/a | −$22.11 | |
| Q3 FY24 | −$4.92 | n/a | −$25.08 | |
| Q2 FY24 | −$7.10 | n/a | −$25.50 | |
| Q1 FY24 | −$7.38 | n/a | −$23.09 | |
| Q4 FY23 | −$5.68 | n/a | −$19.94 | |
| Q3 FY23 | −$5.34 | n/a | −$19.24 |
Against its peers
Companies in Drug Manufacturers - General nearest Madrigal Pharmaceuticals' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| MDGLMadrigal Pharmaceuticals | −$12.87 | |
| BMRNBiomarin Pharmaceutical | $0.37 | −89% a year |
| CORTCorcept Therapeutics | $0.42 | −63% a year |
| PTGXProtagonist Therapeutics | $1.03 | +47% a year |
| TGTXTG Therapeutics | $2.74 | +641% a year |
| ALKSAlkermes plc. | $0.38 | −82% a year |
| JAZZJazz Pharmaceuticals | $14.62 | |
| AMRXAmneal Pharmaceuticals | $0.49 | +4800% a year |
| LGNDLigand Pharmaceuticals | $9.40 | |
| KNSAKiniksa Pharmaceuticals International | $0.97 | +2325% a year |
| INDVIndivior Pharmaceuticals | $2.78 | +227% a year |
| Peer median | $1.00 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Madrigal Pharmaceuticals
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.